Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 3 1Phase 1/2 1

Status

Terminated 3Completed 2

Sponsor Class

INDUSTRY 5

Study Type

Interventional 5

Sponsor

Cancer Type

Plasma cell 5

Conditions

Immunoglobulin Light-chain Amyloidosis 5Paraproteinemias 1Amyloidosis 1Alzheimer Disease 1

Interventions

pembrolizumab 1033Carboplatin 971Paclitaxel 942Gemcitabine 799Cisplatin 757Docetaxel 698Bevacizumab 637Nivolumab 520Pemetrexed 507Capecitabine 475Cyclophosphamide 473Fluorouracil 425Dexamethasone 410Rituximab 391Oxaliplatin 352Injections 347Trastuzumab 313atezolizumab 312Cetuximab 291Leucovorin 290Irinotecan 271130-nm albumin-bound paclitaxel 257Prednisone 251Ipilimumab 244Doxorubicin 241Lenalidomide 231Fulvestrant 226fludarabine 219durvalumab 211Erlotinib Hydrochloride 196

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
INDUSTRY × birtamimab × Clear all
NCT02312206 2023-11-14

VITAL

Prothena Biosciences Ltd.

Phase 3 Terminated
260 enrolled 11 charts
Plasma cell

Immunoglobulin Light-chain Amyloidosis

NCT02613182 2019-05-16

OLE

Prothena Biosciences Ltd.

Phase 2 Terminated
34 enrolled 10 charts
Plasma cell

Immunoglobulin Light-chain Amyloidosis

NCT02632786 2019-04-05

PRONTO

Prothena Biosciences Ltd.

Phase 2 Completed
129 enrolled 18 charts
Plasma cell

Immunoglobulin Light-chain Amyloidosis, Alzheimer Disease, Amyloidosis, Paraproteinemias

NCT03154047 2019-03-26

Study in Subjects With Light Chain (AL) Amyloidosis

Prothena Biosciences Ltd.

Phase 2 Terminated
80 enrolled 9 charts
Plasma cell

Immunoglobulin Light-chain Amyloidosis

NCT01707264 2018-08-28

Phase 1/2, Open Label, Dose Escalation Study of NEOD001 in Subjects With Light Chain (AL) Amyloidosis

Prothena Biosciences Ltd.

Phase 1/2 Completed
69 enrolled
Plasma cell

Immunoglobulin Light-chain Amyloidosis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡